Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Precancerous Conditions 1Keratosis, Actinic 1Carcinoma, Squamous Cell 1

Interventions

Whole-Body Irradiation 4Sulindac 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4fludarabine phosphate 3Selenium 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Cetuximab 3Biopsy 3Tacrolimus 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Polymerase Chain Reaction 2Mycophenolic Acid 2Melphalan 2Gene Expression Profiling 2Etoposide 2Darbepoetin alfa 2Cyclosporine 2Cyclophosphamide 2Cisplatin 2Busulfan 2Aspirin 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2vandetanib 1ruxolitinib 1polyphenon E 1perillyl alcohol 1peginterferon alfa-2b 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precancerous Conditions × Excipients × Clear all
NCT02844777 2023-01-12

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

Vidac Pharma

Phase 2 Completed
93 enrolled 13 charts
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡